Helix BioPharma Corp. (HBP) - Cash Flow Conversion Efficiency

Latest as of January 2026: -0.030x

Based on the latest financial reports, Helix BioPharma Corp. (HBP) has a cash flow conversion efficiency ratio of -0.030x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-456.00K ≈ $-329.86K USD) by net assets (CA$15.36 Million ≈ $11.11 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Helix BioPharma Corp. (HBP) total market value for the company's overall valuation and market capitalisation.

Helix BioPharma Corp. - Cash Flow Conversion Efficiency Trend (2007–2025)

This chart illustrates how Helix BioPharma Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Helix BioPharma Corp. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Helix BioPharma Corp. ranked by their cash flow conversion efficiency. See HBP operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
European Residential Real Estate Investment Trust TO:ERE-UN	0.032x
Kyung Dong Pharmaceutical Co. Ltd KQ:011040	0.021x
Oil Terminal C RO:OIL	0.031x
Tacheng Real Estate Co Ltd TWO:6171	-0.098x
FatPipe, Inc. Common Stock NASDAQ:FATN	-0.026x
BIMobject AB ST:BIM	-0.108x
Knafaim TA:KNFM	0.023x
Swift Haulage Bhd KLSE:5303	0.041x

Annual Cash Flow Conversion Efficiency for Helix BioPharma Corp. (2007–2025)

The table below shows the annual cash flow conversion efficiency of Helix BioPharma Corp. from 2007 to 2025. View HBP stock price and chart for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-07-31	CA$15.59 Million ≈ $11.27 Million	CA$-3.83 Million ≈ $-2.77 Million	-0.246x	-100.42%
2024-07-31	CA$-90.00K ≈ $-65.10K	CA$-5.22 Million ≈ $-3.78 Million	57.989x	+785.52%
2023-07-31	CA$-844.00K ≈ $-610.54K	CA$-5.53 Million ≈ $-4.00 Million	6.549x	+132.09%
2022-07-31	CA$319.00K ≈ $230.76K	CA$-6.51 Million ≈ $-4.71 Million	-20.404x	-405.50%
2021-07-31	CA$-1.39 Million ≈ $-1.01 Million	CA$-9.30 Million ≈ $-6.73 Million	6.679x	+283.91%
2020-07-31	CA$2.98 Million ≈ $2.16 Million	CA$-10.83 Million ≈ $-7.83 Million	-3.632x	-315.43%
2019-07-31	CA$-3.28 Million ≈ $-2.37 Million	CA$-5.53 Million ≈ $-4.00 Million	1.686x	-65.79%
2018-07-31	CA$-1.53 Million ≈ $-1.10 Million	CA$-7.52 Million ≈ $-5.44 Million	4.927x	-99.10%
2017-07-31	CA$-17.00K ≈ $-12.30K	CA$-9.29 Million ≈ $-6.72 Million	546.765x	+19640.99%
2016-07-31	CA$3.16 Million ≈ $2.29 Million	CA$-8.85 Million ≈ $-6.40 Million	-2.798x	-125.05%
2015-07-31	CA$6.83 Million ≈ $4.94 Million	CA$-8.49 Million ≈ $-6.14 Million	-1.243x	-10.09%
2014-07-31	CA$6.81 Million ≈ $4.93 Million	CA$-7.69 Million ≈ $-5.56 Million	-1.129x	+28.89%
2013-07-31	CA$4.92 Million ≈ $3.56 Million	CA$-7.81 Million ≈ $-5.65 Million	-1.588x	+29.95%
2012-07-31	CA$6.22 Million ≈ $4.50 Million	CA$-14.11 Million ≈ $-10.21 Million	-2.267x	-384.94%
2011-07-31	CA$22.11 Million ≈ $16.00 Million	CA$-10.34 Million ≈ $-7.48 Million	-0.468x	+39.56%
2010-07-31	CA$15.76 Million ≈ $11.40 Million	CA$-12.19 Million ≈ $-8.82 Million	-0.774x	-0.33%
2009-07-31	CA$17.06 Million ≈ $12.34 Million	CA$-13.16 Million ≈ $-9.52 Million	-0.771x	-126.16%
2008-07-31	CA$20.52 Million ≈ $14.85 Million	CA$-7.00 Million ≈ $-5.06 Million	-0.341x	+28.58%
2007-07-31	CA$12.73 Million ≈ $9.21 Million	CA$-6.08 Million ≈ $-4.40 Million	-0.477x	--

About Helix BioPharma Corp.

TO:HBP Canada Biotechnology

Market Cap

$80.11 Million

CA$110.75 Million CAD

Market Cap Rank

#20165 Global

#688 in Canada

Share Price

CA$1.45

Change (1 day)

+3.57%

52-Week Range

CA$1.33 - CA$5.31

All Time High

CA$11.25